Cantor Fitzgerald analyst Carter Gould downgraded Amgen (AMGN) to Neutral from Overweight with a price target of $305, down from $340, as the analyst took over coverage of the stock.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen downgraded to Neutral from Overweight at Cantor Fitzgerald
- Dow Jones Index Today: UnitedHealth Drags Down DIA Stock
- Amgen price target raised to $319 from $315 at UBS
- Sandoz files antitrust litigation against Amgen regarding Enbrel
- Amgen says Phase 3 DeLLphi-304 trial of Imdelltra met primary endpoint